Free Trial
→ First Look: Elon’s “Starphone” (From Stansberry Research) (Ad)tc pixel
NYSEAMERICAN:IBO

Impact Biomedical Q1 2026 Earnings Results & Report

$4.25 +0.14 (+3.41%)
Closing price 10/9/2026 04:10 PM Eastern
Extended Trading
$4.28 +0.03 (+0.59%)
As of 10/9/2026 07:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Impact Biomedical reported Q1 2026 earnings on May 12, 2026. The company reported EPS of -$0.2524, while revenue was $0.01 million.

Research:ProfileEarnings History

Earnings Announcement Details

Quarter
Q1 2026
Report Date
Time
After Market Closes
Conference Call
7:00 AM ET

Impact Biomedical EPS Results

Actual EPS
-$0.2524
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Impact Biomedical Revenue Results

Actual Revenue
$0.01 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

Impact Biomedical's Q1 2026 Quarterly reportQuarterly report
(10-Q)

Impact Biomedical Q1 2026 Earnings FAQ

Impact Biomedical (NYSEAMERICAN:IBO) reported earnings of -$0.2524 per share for Q1 2026. The report was announced on Tuesday, May 12, 2026.

Impact Biomedical reported revenue of $0.01 million for Q1 2026.

Impact Biomedical Earnings Headlines

Impact BioMedical advances merger with Zoar Limited
September 17, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/impact-biomedical-advances-merger-with-zoar-limited?utm_source=marketbeat.com&utm_medium=referral
Impact Biomedical Files Form F-4 For Proposed Zoar Business Combination
September 16, 2026  |  rttnews.comhttps://www.rttnews.com/3691563/impact-biomedical-files-form-f-4-for-proposed-zoar-business-combination.aspx
If you keep cash in a U.S. bank account… read this NOW
Since 2020, U.S. banks have been required to keep zero percent of deposits on hand, lending out nearly every dollar while paying savers just 0.04 percent interest. A new law, the GENIUS Act signed last summer, has cleared the way for a different kind of money to emerge this fall, one that could offer savings rates up to 6 percent. See what Ian King, Chief Strategist at Strategic Fortunes, has uncovered about this shift before it goes live.tc pixel
 |  Banyan Hill Publishing (Ad)
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
September 16, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/impact-biomedical-inc-announces-filing-132000551.html
Impact Biomedical Inc. Announces Filing of F-4 Registration Statement for Proposed Business Combination with Zoar Limited
September 16, 2026  |  quiverquant.comQ
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley's Limited)
September 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/16/3363262/0/en/impact-biomedical-inc-announces-filing-of-form-f-4-registration-statement-in-connection-with-proposed-merger-with-zoar-ltd-f-k-a-dr-ashley-s-limited.html
See More Impact Biomedical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Impact Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Impact Biomedical and other key companies, straight to your email.

About Impact Biomedical

Impact Biomedical (NYSEAMERICAN:IBO), Inc. is a biotechnology and life sciences company focused on developing and commercializing biomedical technologies, pharmaceutical products and related health solutions. Its activities have included research into antiviral, antimicrobial and anti-inflammatory applications, with an emphasis on technologies intended to address infectious diseases and other public health needs.

The company has described a portfolio of biomedical intellectual property and development programs rather than a broad portfolio of established commercial products. Its work has included potential therapeutics, preventive technologies and other health-related applications developed independently or through research and commercialization relationships.

Impact Biomedical is publicly traded on the NYSE American under the symbol IBO. Publicly available information about its operating geographies, commercial scale and current leadership is limited, and the company appears to remain primarily focused on research, development and the potential commercialization of its technology portfolio.

View Impact Biomedical Profile
Earnings Tools